Clinical trial NCT06269705: ZILRETTA in Subjects With Shoulder Osteoarthritis
Official title: A Study to Evaluate the Efficacy and Safety of ZILRETTA in Subjects With Glenohumeral Osteoarthritis
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE3
Conditions: Glenohumeral Osteoarthritis
Keywords: Glenohumeral Osteoarthritis
Lead sponsor: Pacira Pharmaceuticals, Inc
Sponsor class: INDUSTRY
First posted: 2024-02-21
Enrollment: 250
Sex: ALL
Minimum age (years): 50
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Primary Objective: To assess the efficacy of ZILRETTA on pain following an intra-articular (IA) injection in subjects with glenohumeral osteoarthritis (OA) relative to normal saline placebo

Secondary Objective:

* To assess the efficacy of ZILRETTA on pain following an IA injection in subjects with glenohumeral OA relative to triamcinolone acetonide injectable suspension, immediate release (TCA-IR) and normal saline placebo
* To assess the safety of ZILRETTA in subjects with glenohumeral OA relative to normal saline placebo and TCA-IR

Detailed description: This is a multi-center, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of ZILRETTA in subjects with glenohumeral OA. This study will be conducted at approximately 25 study sites in the United States. Subjects will be screened to confirm the diagnosis of OA and eligibility based on the Inclusion and Exclusion Criteria. Approximately 250 male or female subjects, 50 to 80 years of age inclusive, will be enrolled, randomized to 1 of 3 treatment groups (2:2:1), and treated with a single IA injection of either:

* Treatment Arm 1: 32 mg ZILRETTA,
* Treatment Arm 2: 40 mg Immediate Release Triamcinolone (TCA-IR), or
* Treatment Arm 3: placebo (normal saline). ZILRETTA, TCA-IR, or normal saline placebo will be administered as a single IA injection with a 24-week follow-up period with a primary endpoint at Week 12.

The study will involve a Screening period (a minimum of 10 days, up to a maximum of 35 days), pre-treatment phase, dosing at Baseline/Day 1, and 8 additional outpatient visits at Weeks 2, 4, 8, 12, 16, 18, 20, and 24/End of Study (EOS) during the study.

At specified times throughout the study, subjects will undergo physical examinations, index shoulder assessments, and index shoulder X-rays; blood will be collected for laboratory safety tests; and vital signs will be collected.

Information regarding adverse events (AEs) and prior and concomitant medications and treatments will be collected from the time of signing the Informed Consent Form (ICF) through the Week 24/EOS visit. Information regarding rescue medication usage, Average and Worst daily Pain score (0-10 Numeric Rating Scale (NRS); 0 = no pain, 10 = worst possible pain) in the index shoulder, and Sleep Interference (SI) will be completed daily via an electronic diary (eDiary) and reviewed for compliance by site staff at each study visit.

At the Screening Visit, subjects will be registered in the eDiary and receive instructions on its use. Subjects will complete accurate pain reporting (APR) and placebo response reduction (PRR) training prior to completing all questionnaires.

Eligibility criteria: Inclusion Criteria:

1. Written informed consent has been obtained prior to initiating any study-specific procedures.
2. Willingness and ability to comply with the study procedures and visit schedules and ability to follow verbal and written instructions, including eDiary questionnaire completion requirements.
3. Subjects 50 to 80 years of age, inclusive, on the day of consent.
4. Body Mass Index (BMI) ≤40 kg/m2.
5. Symptoms (including pain) associated with OA of the index shoulder for ≥3 months prior to Screening Visit (subject self-report is acceptable).
6. Shoulder pain due to OA for \>15 days over the last month (as reported by the subject).
7. Grade 2 or 3 OA in the index glenohumeral joint based on the Samilson-Prieto classification system as confirmed by X-ray (axillary view and true anterior-posterior view) taken at, or within 6 months of, the Screening Visit and read by the central reader.
8. Average daily mean pain score ≥4.0 and ≤9.0 in index shoulder (0-10 numeric rating scale \[NRS\]) using the average daily ratings for at least 4 out of the 7 days prior to Baseline/Day 1.
9. Average Shoulder Pain and Disability Index (SPADI) pain score ≥5.0 and ≤9.0 in index shoulder prior to Baseline/Day 1.
10. Willingness to abstain from use of protocol-specified restricted medications and therapies during the study.
11. Sexually active males or females of childbearing potential must agree to use a highly effective method of contraception throughout the duration of the study. Females of childbearing potential are defined as females who are not surgically sterile or postmenopausal (defined as 12 consecutive months with no menses without an alternative medical cause) as documented in medical history. Highly effective methods of contraception include abstinence; oral, injected, or implanted hormonal methods of contraception; intrauterine device or intrauterine system; condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository; or monogamous intercourse with a partner who is surgically sterile (post-vasectomy, -hysterectomy, or -tubal ligation).

Exclusion Criteria:

Disease-related criteria

1. Subjects who cannot washout of prohibited medications (eg, opioids, other analgesics, and tetrahydrocannabinol (THC) and cannabidiol (CBD) containing products) or restricted medications.
2. Has symptomatic arthritis in other joints of the index shoulder (eg, acromioclavicular joint, sternoclavicular joint, or scapulothoracic joint), which is the primary source of pain in the opinion of the Investigator.
3. Has symptomatic rotator cuff pathology by physical examination or evidence of cuff tear arthropathy by radiograph.
4. Has clinical symptomatic chronic bilateral shoulder pain (any condition causing pain in the non- index shoulder).
5. Has a subchondral bone insufficiency fracture or humeral head necrosis/collapse (including bone infarct) in the index shoulder based on X-ray used for study qualification.
6. Has a prior ipsilateral proximal humerus fracture or scapula fracture to the index shoulder within 2 years of Screening Visit.
7. Has been diagnosed with adhesive capsulitis ("frozen shoulder") in the index shoulder, within 1 year of the Screening Visit.
8. Has a previous shoulder injury (eg, dislocation or clavicle fracture) in the index shoulder which resulted in functional limitation ≥1 month prior to the Screening Visit.
9. Prior surgery on the index shoulder (less than 5 years), either open or arthroscopic. Should not have any retained hardware.
10. Has an index shoulder with major dysplasia or congenital abnormality, osteochondritis dissecans, acromegaly, ochronosis, hemochromatosis, Wilson's disease, primary osteochondromatosis, chondrolysis from a pain pump, or a history of avascular necrosis with secondary OA.
11. Has current or history of infection (eg, osteomyelitis) in the index shoulder or current skin infection at injection site.
12. Has any concurrent chronic pain condition within 1 month prior to the Screening Visit (subject self- report acceptable), including but not limited to, cervical spine pain or conditions causing radicular pain or peripheral nerve injury/entrapment (eg, brachial plexus injury or suprascapular nerve entrapment); diabetic neuropathy; post-herpetic neuralgia; post-stroke pain; or fibromyalgia that may affect sensation of the index shoulder.
13. painDETECT Questionnaire (PD-Q) score \>18 during Screening Visit.
14. History or current evidence of reactive arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or arthritis associated with inflammatory bowel disease, systemic lupus erythematosus, or calcium pyrophosphate dihydrate crystal deposition (CPPD), gout, or other autoimmune diseases.
15. Any planned surgeries in the upper limbs and/or cervical spine during the study period, or any other surgery during the study period that would require use of a restricted medication.

    Previous or concomitant treatment-related criteria
16. Presence of surgical hardware or other foreign body due to open or arthroscopic cartilage transplant or bone grafting procedures in the index shoulder.
17. Use of muscle relaxants (eg, cyclobenzaprine, tetrazepam, and diazepam) and topical therapies (eg, NSAIDs, CBD oil, capsaicin, lidocaine patches, or other local treatments) applied to the index shoulder.
18. The use corticosteroids as follows:

    * IA corticosteroid in the index shoulder within 3 months of Screening Visit.
    * Intrabursal and intratendinous corticosteroids in the index shoulder within 6 months of Screening Visit.
    * Intravenous (IV), Intramuscular (IM), or epidural corticosteroids within 6 months of Screening.
    * Oral corticosteroids within 1 month of Screening.
19. IA treatment of index shoulder with any of the following agents within 6 months of Screening: hyaluronic acid (investigational or marketed) or any biologic agent (eg, platelet rich plasma \[PRP\] injection, stem cells, prolotherapy, and amniotic fluid-derived product).
20. Significant changes with regard to physical activity, physical therapy, or lifestyle within 1 month of the Screening Visit, or any planned changes throughout the duration of the study.
21. Use of selective serotonin/norepinephrine reuptake inhibitors (SSRIs/SNRIs) (eg, fluoxetine, fluvoxamine, citalopram, escitalopram, sertraline, duloxetine, and venlafaxine, milnacipran) if the dose is not stable for at least 3 months prior to Screening Visit and must remain stable throughout the study.
22. Any treatment with acupuncture and/or transcutaneous electrical nerve stimulation (TENS) within 3 months of Screening Visit.

    Subject-related criteria
23. Females who are pregnant or nursing or plan to become pregnant within 12 months after dosing; men whose partner plans to conceive within 12 months after dosing.
24. Subjects with clinically relevant level of pain catastrophizing defined as Pain Catastrophizing Scale (PCS) score of ≥30 at Screening Visit.
25. Known or suspected hypersensitivity to any form of triamcinolone or poly (lactic-co-glycolic) acid (PLGA).
26. Laboratory evidence of infection with human immunodeficiency virus (HIV), positive test for hepatitis B surface antigen (HBsAg), or positive serology for hepatitis C virus (HCV) with positive test for HCV ribonucleic acid (RNA) on recent testing.
27. A medical history suggesting the subject will or is likely to require a course of systemic corticosteroids during the study.
28. History or evidence of active or latent systemic fungal or mycobacterial infection (including tuberculosis) or of ocular herpes simplex.
29. History of sarcoidosis, amyloidosis or active Cushing's syndrome.
30. Use of immunomodulators, immunosuppressives, or chemotherapeutic agents within 5 years of Screening.
31. Active or history of malignancy within 5 years of Screening, with the exception of resected basal cell carcinoma, squamous cell carcinoma of the skin, or effectively managed cervical carcinoma.
32. History of radiation treatment involving the index shoulder girdle.
33. Active substance abuse (drugs or alcohol) or history of substance abuse within the past 12 months of Screening.
34. Has received a live vaccine within 3 months of Baseline/Day 1.
35. Has received vaccination within 1 week prior to the Screening Visit and local injection pain has not resolved.
36. Use of any other investigational drug, biologic, or device within 3 months of Screening Visit.
37. Any bacterial or viral infection requiring IV antibiotics within 4 weeks of Baseline/Day 1 or oral antibiotics within 2 weeks of Baseline/Day 1.
38. Any other clinically significant acute or chronic medical conditions (eg, poorly controlled diabetes with hemoglobin A1c \[HbA1c\] of greater than 9.5%) that, in the judgment of the Investigator, could compromise subject safety, preclude the use of an IA corticosteroid, limit the subject's ability to complete the study, or compromise the objectives of the study.
39. Subjects contraindicated to the use of acetaminophen/paracetamol (allowed rescue pain medicine) per National Product Labeling and Investigator's judgment.
40. Investigator or any subinvestigator, research assistant, pharmacist, study coordinator, or other staff or relative thereof directly involved in the conduct of the study.

Primary outcomes:
measure: Change from Baseline on the Worst Daily Pain (24-hr) mean score (0-10 Numeric Rating Scale (NRS); 0 = no pain, 10 = worst possible pain) at Week 12 for ZILRETTA relative to placebo
timeFrame: Week 12
Secondary outcomes:
measure: Change from Baseline on the Worst Daily Pain (24-hr) mean score (0-10 Numeric Rating Scale (NRS); 0 = no pain, 10 = worst possible pain) at Week 12 for ZILRETTA relative to TCA-IR
timeFrame: Week 12
measure: Change from Baseline on the Worst Daily Pain (24-hr) mean score (0-10 Numeric Rating Scale (NRS); 0 = no pain, 10 = worst possible pain) at Week 18 for ZILRETTA relative to TCA-IR
timeFrame: Week 18
measure: Change from Baseline on the Worst Daily Pain (24-hr) mean score (0-10 Numeric Rating Scale (NRS); 0 = no pain, 10 = worst possible pain) at Week 2 for ZILRETTA relative to placebo
timeFrame: Week 2
measure: Change from Baseline on the Worst Daily Pain (24-hr) mean score (0-10 Numeric Rating Scale (NRS); 0 = no pain, 10 = worst possible pain) at Week 4 for ZILRETTA relative to placebo
timeFrame: Week 4
measure: Change from Baseline on the Worst Daily Pain (24-hr) mean score (0-10 Numeric Rating Scale (NRS); 0 = no pain, 10 = worst possible pain) at Week 8 for ZILRETTA relative to placebo
timeFrame: Week 8
measure: Change from Baseline at Week 12 on the Shoulder Pain and Disability Index (SPADI) total score and subscales (0-10 Numeric Rating Scale (NRS); 0 = no pain, 10 = worst possible pain) for ZILRETTA relative to placebo
timeFrame: Week 12
measure: Change from Baseline at Week 12 on the SPADI total score and subscales (0-10 Numeric Rating Scale (NRS); 0 = no pain, 10 = worst possible pain) for ZILRETTA relative to TCA-IR
timeFrame: Week 12
Other outcomes:
Locations:
city: Vestavia Hills
country: United States
facility: Alabama Orthopaedic Center- Research
state: Alabama
city: Surprise
country: United States
facility: Onyx Clinical Research
state: Arizona
city: Tucson
country: United States
facility: Tucson Orthopaedic Institute (TOI) - East Office
state: Arizona
city: La Mesa
country: United States
facility: Horizon Clinical Research
state: California
city: Napa
country: United States
facility: Napa Pain Institute
state: California
city: Redwood City
country: United States
facility: Stanford University - Sports Medicine Clinic
state: California
city: Washington
country: United States
facility: International Spine, Pain & Performance Center
state: District of Columbia
city: Atlantis
country: United States
facility: Orthopedic Center of Palm Beach City
state: Florida
city: Miami
country: United States
facility: Baptist Health Orthopedic Care - Miami Gardens
state: Florida
city: Miami
country: United States
facility: Infinite Clinical Research
state: Florida
city: Sarasota
country: United States
facility: Gulfcoast Research Institute
state: Florida
city: Tampa
country: United States
facility: Clinical Research of West Florida
state: Florida
city: West Palm Beach
country: United States
facility: Hospital for Special Services
state: Florida
city: Boise
country: United States
facility: Injury Care Research
state: Idaho
city: Overland Park
country: United States
facility: Kansas City Bone & Joint Clinic - Overland Park
state: Kansas
city: New Orleans
country: United States
facility: Ochsner Sports Medicine Institute
state: Louisiana
city: Boston
country: United States
facility: New England Baptist Hospital
state: Massachusetts
city: Troy
country: United States
facility: Oakland Medical Center
state: Michigan
city: Saint Louis
country: United States
facility: Sundance Clinical Research
state: Missouri
city: Flushing
country: United States
facility: New York-Presbyterian Queens
state: New York
city: Morehead City
country: United States
facility: West Clinical Research
state: North Carolina
city: Cincinnati
country: United States
facility: University of Cincinnati
state: Ohio
city: Columbus
country: United States
facility: Ohio State University
state: Ohio
city: Altoona
country: United States
facility: University Orthopedics Center
state: Pennsylvania
city: Duncansville
country: United States
facility: Altoona Arthritis &amp; Osteoporosis Center - Altoona Center for Clinical Research
state: Pennsylvania
city: State College
country: United States
facility: University Orthopedics Center (UOC) - State College
state: Pennsylvania
city: Charleston
country: United States
facility: Medical University Health - West Ashley Medical Pavilion
state: South Carolina
city: Bedford
country: United States
facility: Texas Orthopedic Specialists, PLLC
state: Texas
city: Bellaire
country: United States
facility: First Surgical Hospital
state: Texas
city: El Paso
country: United States
facility: El Paso Clinical Trials, LLC
state: Texas
city: Draper
country: United States
facility: Physicians Research Options
state: Utah
city: Danville
country: United States
facility: Spectrum Medical
state: Virginia
Study officials:
affiliation: Pacira Pharmaceuticals, Inc
name: Nino Joy, MD
role: STUDY_DIRECTOR
References: